Tyche Industries Ltd. engages in the manufacture and processing of active pharmaceutical ingredients and intermediates. The company is headquartered in Hyderabad, Telangana. The company went IPO on 2000-09-25. The firm operates through the Bulk Drugs segment. Its APIs include Sertraline HCI, Racecadotril, Palonosetron HCI, Silodosin, Solifenacin Succinate, Tamsulosin HCI, Tenofovir Disoproxil Fumarate, Tenofovir Alafenamide Fumarate, Atazanavir, Rupatadine Fumarate, Glucosamine HCI, Glucosamine Sulfate KCL, Glucosamine Sulfate NaCl, Nitrofurantoin Monohydrate, Nitrofurantoin Anhydrous and Nitrofurantoin Macrocrystal and others. Its intermediates include 4-(3,4-Dichlorophenyl)-1-tetralone, 1-Benzylpiperidine-4-Carboxaldehyde (BPCA), 3-Hydroxymethyl quinuclidine Hcl, and others. Its chiral intermediates include S-(+)-3-Quinuclidinol, R-(-)-3-Quinuclidinol and others. The firm's nutraceuticals include Glucosamine Hydrochloride, Glucosamine Sulphate Potassium Chloride and Glucosamine Sulphate Sodium Chloride.
Loading chart…
This company hasn't held an earnings call in the last six months, so there's no recent commentary from management. Our deep dives are built on what management actually said, so we haven't prepared one.